Evidence map›Paper›PMID 37675143›Full record

ArticleFrontiers in cell and developmental biology2023

Non-IgE-reactive allergen peptides deteriorate the skin barrier in house dust mite-sensitized atopic dermatitis patients.

Karin Pfisterer, Matthias Wielscher, David Samardzic, Pauline Weinzettl, Dorte Symmank, Lisa E Shaw, Raffaela Campana, Huey-Jy Huang, Matthias Farlik, Christine Bangert and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Allergen-specific circulating CLAFrontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Karin PfistererDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Matthias WielscherDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
David SamardzicDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Pauline WeinzettlDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Dorte SymmankDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Lisa E ShawDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Raffaela CampanaDepartment of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria.
Huey-Jy HuangDepartment of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria.
Matthias FarlikDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Christine BangertDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Susanne VrtalaDepartment of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria.
Rudolf ValentaDepartment of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria.
Wolfgang WeningerDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Medical University of Vienna · ATKarl Landsteiner University of Health Sciences · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by type 2 cytokine-driven skin inflammation and epithelial barrier dysfunction. The latter is believed to allow the increased penetration of chemicals, toxins, and allergens into the skin. House dust mite allergens, particularly Der p 2, are important triggers in sensitized individuals with AD; the precise actions of these allergens in epithelial biology remain, however, incompletely understood. In this study, we compared the effects of the protein allergen Der p 2 and a mix of non-IgE-reactive Der p 2 peptides on skin cells using patch tests in AD patients and healthy participants. We then analyzed mRNA expression profiles of keratinocytes by single-cell RNA-sequencing. We report that existing barrier deficiencies in the non-lesional skin of AD patients allow deep penetration of Der p 2 and its peptides, leading to local microinflammation. Der p 2 protein specifically upregulated genes involved in the innate immune system, stress, and danger signals in suprabasal KC. Der p 2 peptides further downregulated skin barrier genes, in particular the expression of genes involved in cell-matrix and cell-cell adhesion. Peptides also induced genes involved in hyperproliferation and caused disturbances in keratinocyte differentiation. Furthermore, inflammasome-relevant genes and IL18 were overexpressed, while KRT1 was downregulated. Our data suggest that Der p 2 peptides contribute to AD initiation and exacerbation by augmenting hallmark features of AD, such as skin inflammation, barrier disruption, and hyperplasia of keratinocytes.

Indexed as

allergen response in the skinallergyatopic dermatitisDer p 2epithelial barrier disruptionhouse dust mitekeratinocytesskin barrier

Identifiers

PMID37675143
PMCPMC10478000
OpenAlexW4386070080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.